With 86% Ownership, Gilead Sciences, Inc. (NASDAQ:GILD) Boasts of Strong Institutional Backing

Key Insights Significantly high institutional ownership implies Gilead Sciences' stock price is sensitive to their trading actions 50% of the business is held by the top 15 shareholders Ownership

Simply Wall St00:48

Gilead's Trodelvy Falls Short in Significantly Improving Overall Survival in NSCLC

Seeking AlphaMay 31 23:06

Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

On Thursday, Gilead Sciences Inc (NASDAQ:GILD) announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).The TROPiCS-04 study e

BenzingaMay 31 21:27

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an or

BenzingaMay 31 20:16

Express News | Gilead Sciences: Evoke-01 Evaluating Trodelvy Vs Docetaxel Showed 16% Reduction in Risk of Death in Patients With Metastatic or Advanced Nsclc

BreakingsMay 31 20:00

Express News | Gilead Sciences: Safety Profile for Trodelvy Consistent With Prior Studies, No New Safety Signals Identified

BreakingsMay 31 20:00